Lantheus Holdings Inc. entered a strategic crossroads after Curium submitted a non‑binding offer that values the radiopharmaceutical firm at roughly $7 billion. Sources familiar with the talks say the proposal prompted Lantheus’s board to explore a sale, weighing the premium against recent market performance and shareholder expectations. The proposal also sparks speculation about potential synergies in global distribution and regulatory approvals.

The bid arrives as the diagnostic imaging sector enjoys robust demand, driven by expanding use of PET tracers in oncology and neurology. If the transaction closes, Curium would acquire Lantheus’s pipeline of radiotracers and its manufacturing footprint, potentially reshaping competitive dynamics and creating scale advantages in a niche but high‑margin market. Such scale could lower costs, accelerate FDA submissions, and broaden market reach for firms.

Investors will watch the price negotiation closely, as a deal near $7 billion would represent one of the largest recent moves in the niche radiopharma space and could trigger valuation reassessments for peers. A completed sale would deliver a premium to Lantheus shareholders while giving Curium access to products and R&D assets. The transaction also raises antitrust scrutiny given Curium’s existing holdings in related imaging technologies.